



Urovant Sciences to Present at the H.C. Wainwright & Co. Annual Global Investment Conference

September 8, 2020

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Sep. 8, 2020-- Urovant Sciences (Nasdaq: UROV) announced today that president and chief executive officer James Robinson will give a presentation at 7:30 a.m. Pacific / 10:30 a.m. Eastern on Tuesday, September 15, 2020, at the H.C. Wainwright & Co. Annual Global Investment Conference, which is being held virtually.

A live, audio webcast for this event will be available on the Investor Relations section of the Company's website at <http://ir.urovant.com>. A replay of the webcast will be available for approximately 30 days.

About Urovant Sciences

Urovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions. The Company's lead product candidate, vibegron, is an oral, once-daily small molecule beta-3 agonist that is being evaluated for overactive bladder (OAB). Urovant Sciences reported positive data from the vibegron 12-week, phase 3 pivotal EMPOWUR study and demonstrated favorable longer-term efficacy, safety, and tolerability in a 40-week extension study. The Company submitted a New Drug Application to the FDA seeking approval of vibegron for the treatment of patients with OAB in December 2019. Vibegron is also being evaluated for treatment of OAB in men with benign prostatic hyperplasia (OAB+BPH) and for abdominal pain associated with irritable bowel syndrome (IBS). Urovant's second product candidate, URO-902, is a novel gene therapy being developed for patients with OAB who have failed oral pharmacologic therapy. Urovant Sciences, a subsidiary of Sumitomo Dainippon Pharma Co., Ltd., intends to develop novel treatments for additional urologic diseases. Learn more about us at www.urovant.com.

About Sumitovant Biopharma Ltd.

Sumitovant is a global biopharmaceutical company with offices in New York City and London. Sumitovant is a wholly owned subsidiary of Sumitomo Dainippon Pharma. Sumitovant is the majority shareholder of Urovant and Myovant, and wholly owns Enzyvant, Spirovant, and Altavant. Sumitovant's promising pipeline is comprised of early-through late-stage investigational medicines across a range of disease areas targeting high unmet need. For further information about Sumitovant, please visit <https://www.sumitovant.com>.

About Sumitomo Dainippon Pharma Co., Ltd.

Sumitomo Dainippon Pharma is among the top-ten listed pharmaceutical companies in Japan, operating globally in major pharmaceutical markets, including Japan, the U.S., China, and the European Union. Sumitomo Dainippon Pharma is based on the 2005 merger between Dainippon Pharmaceutical Co., Ltd., and Sumitomo Pharmaceuticals Co., Ltd. Today, Sumitomo Dainippon Pharma has more than 6,000 employees worldwide. Additional information about Sumitomo Dainippon Pharma is available through its corporate website at <https://www.ds-pharma.com>.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20200908005383/en/): <https://www.businesswire.com/news/home/20200908005383/en/>

Investor and Media Inquiries:

Ryan Kubota

949.769.2706

ryan.kubota@urovant.com

Source: Urovant Sciences